Clinical pharmacokinetics and pharmacodynamics of insulin aspart

Clinical Pharmacokinetics
A Lindholm, L V Jacobsen

Abstract

Insulin aspart is a novel rapid-acting insulin analogue with improved subcutaneous absorption properties when compared with soluble human insulin. Pharmacokinetic studies show an absorption profile with a time to reach peak concentration (t(max)) about half that of human insulin, a peak plasma drug concentration (Cmax) approximately twice as high and shorter residence time. The potency and bioavailability of insulin aspart are similar to those of human insulin. The pharmacokinetics of insulin aspart have been studied in healthy Caucasian and Asian-Japanese volunteers, in patients with type 1 and 2 diabetes mellitus, and in children with diabetes, with both pre- and postprandial administration and during continuous subcutaneous insulin infusion (CSII). The pharmacokinetic profile was similar to that of another rapid-acting insulin analogue, insulin lispro, on the basis of published information for that agent. Pharmacodynamic studies show a smaller excursion of postprandial glucose with insulin aspart injected subcutaneously just before the meal compared with soluble human insulin injected 30 minutes before the meal in patients with type 1 diabetes mellitus, and an equivalent control in patients with type 2 diabetes displaying re...Continue Reading

References

Nov 1, 1979·Diabetologia·T LauritzenC Binder
Jan 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·R B Tattersall, G V Gill
Jul 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·P H de MeijerA van't Laar
Aug 1, 1988·Endocrine Reviews·W C Duckworth
Mar 1, 1984·Diabetes Care·C BinderS Pramming
Jun 1, 1983·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·K KølendorfT Deckert
Jul 1, 1995·Diabetes Care·P G Clauson, B Linde
Oct 1, 1995·Clinical Pharmacology and Therapeutics·D C HoweyJ R Woodworth
Dec 1, 1994·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·L Heinemann, F J Ampudia-Blasco
Jul 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·L HeinemannA A Starke
Jul 1, 1996·Diabetic Medicine : a Journal of the British Diabetic Association·L HeinemannT Heise
Oct 25, 1996·The Medical Letter on Drugs and Therapeutics
Aug 1, 1997·Diabetic Medicine : a Journal of the British Diabetic Association·J L MarquesS R Heller
Jun 6, 2000·Advanced Drug Delivery Reviews·J Brange, A Vølund
Jun 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·G A BrunnerT R Pieber
Aug 3, 2000·European Journal of Pediatrics·H B MortensenB Hylleberg
Dec 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·P D HomeUNKNOWN European Insulin Aspart Study Group
Jul 5, 2005·Expert Opinion on Investigational Drugs·S GammeltoftP Kurtzhals

❮ Previous
Next ❯

Citations

Aug 26, 2006·Medical & Biological Engineering & Computing·Pier Giorgio FabiettiEugenio Sarti
May 15, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Zafar A LatifPradana Soewondo
Jun 13, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hoosen RandereeJihad Haddad
Jan 5, 2006·Diabetes & Metabolism·B Guerci, J P Sauvanet
Feb 16, 2008·Diabetes Technology & Therapeutics·Steven D WittlinUNKNOWN CONTROL Study Group
Aug 14, 2012·Diabetes, Obesity & Metabolism·L NosekT Heise
Jun 9, 2009·Clinical Interventions in Aging·Eltayeb Marouf, Alan J Sinclair
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Satoru Yamada
Oct 22, 2002·Nihon rinsho. Japanese journal of clinical medicine·Mitsuyoshi Namba
May 6, 2005·Treatments in Endocrinology·Therese M ChapmanKaren L Goa
May 26, 2007·Clinical Drug Investigation·Alan Haycox
Apr 25, 2007·Clinical Drug Investigation·S C L Gough, J Tibaldi
Nov 4, 2004·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Rudolf ChlupMartina Reznícková
Oct 4, 2006·Expert Opinion on Drug Metabolism & Toxicology·David Owens, Jiten Vora
Jul 30, 2010·Expert Opinion on Pharmacotherapy·Alberto VerrottiFrancesco Chiarelli
Aug 26, 2011·Expert Opinion on Drug Delivery·Birtha Hansen, Irina Matytsina
Sep 6, 2012·Expert Opinion on Biological Therapy·Zhulin MaTorben Laursen
May 10, 2013·Diabetes Research and Clinical Practice·Wan Mohamad Wan BebakarPradana Soewondo
Sep 8, 2009·Journal of Pharmaceutical and Biomedical Analysis·Signe Beck PetersenOle Skyggebjerg
Apr 1, 2008·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Santiago Durán GarcíaAlfonso Pumar López
Sep 27, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert E ArianoSheryl A Zelenitsky
Jan 26, 2005·European Journal of Internal Medicine·Bernhard O BoehmPhilip D Home
Feb 7, 2002·Expert Opinion on Pharmacotherapy·Simon HellerAnders Lindholm
Jun 25, 2002·Best Practice & Research. Clinical Gastroenterology·Anders Lindholm
May 24, 2014·Diabetes Care·George Grunberger
Feb 10, 2011·Journal of Diabetes Science and Technology·Charlotte A IhloTorben Laursen
Dec 7, 2010·Journal of Diabetes Science and Technology·Jessica R CastleW Kenneth Ward
Sep 3, 2013·Therapeutic Advances in Endocrinology and Metabolism·Felix Kulozik, Christoph Hasslacher
Sep 29, 2018·Journal of Diabetes·Lutz HeinemannSheila M Corrigan
May 10, 2020·Drug Testing and Analysis·Péter JudákKoen Deventer
Aug 24, 2017·Journal of Pharmacokinetics and Pharmacodynamics·Erin J MansellHenrik Madsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.